Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer

Louisa Bolm, Lukas Kaesmann, Tobias Bartscht, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalIn Vivo
Volume31
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Bile Duct Neoplasms
Chemotherapy
Radio
Ducts
Survival
Chemoradiotherapy
Tumors
Survival Rate
Radiotherapy
Therapeutics
Surgery
Neoplasms
Drug Therapy

Keywords

  • Concurrent Radiochemotherapy
  • Local Control
  • Metastases-Free Survival
  • Non-Metastatic Bile Duct Cancer
  • Overall Survival.
  • Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Bolm, L., Kaesmann, L., Bartscht, T., Schild, S. E., & Rades, D. (2017). Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. In Vivo, 31(1), 117-120. https://doi.org/10.21873/invivo.11033

Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. / Bolm, Louisa; Kaesmann, Lukas; Bartscht, Tobias; Schild, Steven E.; Rades, Dirk.

In: In Vivo, Vol. 31, No. 1, 2017, p. 117-120.

Research output: Contribution to journalArticle

Bolm, L, Kaesmann, L, Bartscht, T, Schild, SE & Rades, D 2017, 'Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer', In Vivo, vol. 31, no. 1, pp. 117-120. https://doi.org/10.21873/invivo.11033
Bolm L, Kaesmann L, Bartscht T, Schild SE, Rades D. Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. In Vivo. 2017;31(1):117-120. https://doi.org/10.21873/invivo.11033
Bolm, Louisa ; Kaesmann, Lukas ; Bartscht, Tobias ; Schild, Steven E. ; Rades, Dirk. / Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. In: In Vivo. 2017 ; Vol. 31, No. 1. pp. 117-120.
@article{8de4f4ca62714751bc1ab50df4ae3f04,
title = "Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer",
abstract = "Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56{\%} and 38{\%}, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38{\%} and 19{\%}, while local control rates were 43{\%} and 21{\%}, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.",
keywords = "Concurrent Radiochemotherapy, Local Control, Metastases-Free Survival, Non-Metastatic Bile Duct Cancer, Overall Survival., Radiotherapy",
author = "Louisa Bolm and Lukas Kaesmann and Tobias Bartscht and Schild, {Steven E.} and Dirk Rades",
year = "2017",
doi = "10.21873/invivo.11033",
language = "English (US)",
volume = "31",
pages = "117--120",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer

AU - Bolm, Louisa

AU - Kaesmann, Lukas

AU - Bartscht, Tobias

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2017

Y1 - 2017

N2 - Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.

AB - Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.

KW - Concurrent Radiochemotherapy

KW - Local Control

KW - Metastases-Free Survival

KW - Non-Metastatic Bile Duct Cancer

KW - Overall Survival.

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85015970835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015970835&partnerID=8YFLogxK

U2 - 10.21873/invivo.11033

DO - 10.21873/invivo.11033

M3 - Article

C2 - 28064229

AN - SCOPUS:85015970835

VL - 31

SP - 117

EP - 120

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 1

ER -